Patents Assigned to ABBVIE STEMCENTRX LLC
  • Anti-DPEP3 antibodies and methods of use
    Patent number: 10189910
    Abstract: Provided herein are novel anti-DPEP3 antibodies and antibody drug conjugates (ADC), including derivatives thereof, and methods of using the same to treat proliferative disorders.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: January 29, 2019
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Laura Saunders, Deepti Rokkam, David Liu, Mandy Boontanrart
  • NOVEL SEZ6 MODULATORS AND METHODS OF USE
    Publication number: 20190022241
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: June 11, 2018
    Publication date: January 24, 2019
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: David Liu, Deepti Rokkam, Sheila Bheddah, Javier Lopez-Molina, Laura Saunders
  • NOVEL ANTI-MMP16 ANTIBODIES AND METHODS OF USE
    Publication number: 20190022242
    Abstract: Provided are novel anti-MMP16 antibodies and antibody drug conjugates, and methods of using such anti-MMP16 antibodies and antibody drug conjugates to treat cancer.
    Type: Application
    Filed: December 21, 2016
    Publication date: January 24, 2019
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: SOMDUTTA ROY, SAMUEL A. WILLIAMS, SCOTT J. DYLLA, ZHAO HUANG, LAURA SAUNDERS, DAVID LIU, CASEY FRANKLIN, DAVID COELHO
  • NOVEL ANTI-TNFSF9 ANTIBODIES AND METHODS OF USE
    Publication number: 20190016812
    Abstract: Provided are novel anti-TNFSF9 antibodies and antibody drug conjugates, and methods of using such anti-TNFSF9 antibodies and antibody drug conjugates to treat cancer.
    Type: Application
    Filed: December 21, 2016
    Publication date: January 17, 2019
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: JEFFREY BERNSTEIN, DAVID COELHO, LAURA SAUNDERS, AMY LAYSANG, SAMUEL A, WILLIAMS, DAVID LIU, EARL KIM, ROBERT A. STULL
  • NOVEL ANTI-UPK1B ANTIBODIES AND METHODS OF USE
    Publication number: 20190000969
    Abstract: Provided are novel anti-UPK1B antibodies and antibody drug conjugates, and methods of using such anti-UPK1B antibodies and antibody drug conjugates to treat cancer.
    Type: Application
    Filed: December 21, 2016
    Publication date: January 3, 2019
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: KRISTEN MCKNIGHT, SARAH FONG, SAMUEL A. WILLIAMS, ZHAO HUANG, EARL KIM, ROBERT A. STULL, DAVID COELHO, WADE C. ANDERSON, MARIANNE SANTAGUIDA
  • SITE-SPECIFIC ANTIBODY CONJUGATION METHODS AND COMPOSITIONS
    Publication number: 20180346565
    Abstract: Provided are novel antibody drug conjugates (ADCs), and methods of using such ADCs to treat proliferative disorders.
    Type: Application
    Filed: July 30, 2018
    Publication date: December 6, 2018
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: WILLIAM ROBERT ARATHOON, ISHAI PADAWER, LUIS ANTONIO CANO, VIKRAM NATWARSINHJI SISODIYA, KARTHIK NARAYAN MANI, DAVID LIU
  • Anti-DLL3 antibody drug conjugates for treating cancer
    Patent number: 10137204
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: November 27, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • NOVEL ANTI-EMR2 ANTIBODIES AND METHODS OF USE
    Publication number: 20180327506
    Abstract: Provided are novel anti-EMR2 antibodies and antibody drug conjugates, and methods of using such anti-EMR2 antibodies and antibody drug conjugates to treat cancer.
    Type: Application
    Filed: November 18, 2016
    Publication date: November 15, 2018
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: HOLGER KARSUNKY, HANAN FERNANDO, CASEY FRANKLIN, ROBERT A. STULL, DAVID LIU
  • NOVEL ANTIBODY CONJUGATES AND USES THEREOF
    Publication number: 20180318441
    Abstract: Provided are novel antibody drug conjugates (ADCs), and methods of using such ADCs to treat proliferative disorders.
    Type: Application
    Filed: April 5, 2018
    Publication date: November 8, 2018
    Applicants: ABBVIE STEMCENTRX LLC, MEDIMMUNE LIMITED
    Inventors: Michael TORGOV, Philip Wilson HOWARD
  • ANTI-EFNA4 ANTIBODY-DRUG CONJUGATES
    Publication number: 20180296691
    Abstract: The present invention provides for anti-EFNA4 antibody-drug conjugates and methods for preparing and using the same.
    Type: Application
    Filed: January 22, 2018
    Publication date: October 18, 2018
    Applicants: PFIZER, INC., ABBVIE STEMCENTRX LLC
    Inventors: Marc Isaac DAMELIN, Kiran Manohar KHANDKE, Puja SAPRA, Alexander John BANKOVICH, Scott J. DYLLA
  • Anti-CD324 monoclonal antibodies and uses thereof
    Patent number: 10087258
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: October 2, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Robert A. Stull, Monette Aujay, Orit Foord, Alex Bankovich, Johannes Hampl, Scott J. Dylla, David Liu
  • ANTI-DLL3 ANTIBODY DRUG CONJUGATES AND METHODS OF USE
    Publication number: 20180243435
    Abstract: Provided are novel anti-DLL3 antibodies and antibody drug conjugates, and methods of using such anti-DLL3 antibodies and antibody drug conjugates to treat cancer.
    Type: Application
    Filed: August 19, 2016
    Publication date: August 30, 2018
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: SCOTT J. DYLLA, BRIAN SLINGERLAND, TAE HAN, JOHN PEATTIE, HOLGER KARSUNKY, WADE C. ANDERSON
  • NOVEL MODULATORS AND METHODS OF USE
    Publication number: 20180237512
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of such modulators to treat hyperproliferative disorders are provided.
    Type: Application
    Filed: April 18, 2018
    Publication date: August 23, 2018
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: JOHANNES HAMPL, SCOTT J. DYLLA, ORIT FOORD, ROBERT A. STULL
  • Anti-claudin antibodies and methods of use
    Patent number: 10053511
    Abstract: Provided herein are anti-CLDN antibodies and antibody drug conjugates (ADC), including derivatives thereof, and methods of using the same to treat proliferative disorders.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: August 21, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Marianne Santaguida, Monette Aujay, Laura Saunders, David Liu, Orit Foord, Robert A. Stull, Paul Anthony Escarpe
  • Multispecific constructs
    Patent number: 10047163
    Abstract: Provided are novel multispecific antibody constructs and multispecific antibody drug conjugates (ADCs), and methods of using such antibodies and ADCs to treat cancer. IgG-like bispecific antibodies have different binding specificities on each arm of the antibody. They are similar in structure to monospecific IgGs in that they contain two heavy chains with VH, CH1, CH2 and CH3 regions, and two light chains with VL and CL regions.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: August 14, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventor: David Liu
  • Site-specific antibody conjugation methods and compositions
    Patent number: 10035853
    Abstract: Provided are novel antibody drug conjugates (ADCs), and methods of using such ADCs to treat proliferative disorders.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: July 31, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: William Robert Arathoon, Ishai Padawer, Luis Antonio Cano, Vikram Natwarsinhji Sisodiya, Karthik Narayan Mani, David Liu
  • Modulators and methods of use
    Patent number: 10017565
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyperproliferative disorders are provided.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: July 10, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Scott J. Dylla, Orit Foord, Robert A. Stull, Wade C. Anderson, Saiyou Ohshima
  • NOVEL MODULATORS AND METHODS OF USE
    Publication number: 20180162952
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyperproliferative disorders are provided.
    Type: Application
    Filed: January 29, 2018
    Publication date: June 14, 2018
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: ORIT FOORD, SCOTT J. DYLLA, ROBERT A. STULL, ALEX BANKOVICH, ALEXANDRA LEIDA LIANA LAZETIC, JEFFREY BERNSTEIN
  • SEZ6 modulators and methods of use
    Patent number: 9993566
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: August 27, 2014
    Date of Patent: June 12, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: David Liu, Deepti Rokkam, Sheila Bheddah, Javier Lopez-Molina, Laura Saunders
  • Anti-DLL3 antibody drug conjugates
    Patent number: 9968687
    Abstract: Provided are novel antibody drug conjugates (ADCs), and methods of using such ADCs to treat proliferative disorders.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: May 15, 2018
    Assignees: AbbVie Stemcentrx LLC, Medimmune Limited
    Inventors: Michael Torgov, Philip Wilson Howard